Author

Jose Ignacio Miranda

University of the Basque CountryORCID 0000-0002-7646-6857Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Bioinformatics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Organism:non-human primate· 1 Assay:protein structure· 1 Organism:rat· 1 Approach:simulation· 1 Approach:statistical model· 1

Frequent Co-Authors

Adolfo López de MunainiD· 4 shared Jesús María AizpuruaiD· 4 shared Ainara Vallejo‐IllarramendiiD· 3 shared Francisco Javier Gil-BeaiD· 3 shared Klaudia González-ImaziD· 3 shared Maialen Sagartzazu‐AizpuruaiD· 3 shared Araceli Lara-LópeziD· 2 shared Javier Ruiz‐EderraiD· 2 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersNeuroscience

Adolfo López de MunainORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Computational Analysis of ELOVL6 Structure and Inhibition for Rational Drug Design

Markel G. Ibarluzea, Rafael Ramis, Martin Fuentetaja, Francisco Javier Gil-Bea, Gorka Gereñu, Adolfo López de Munain, Jesús María Aizpurua, Jose Ignacio Miranda, Aitor Bergara, Aritz Leonardo

This study uses computational methods to analyze ELOVL6 structure and inhibition, identifying key residues and binding pathways for drug design.

Journal of Chemical Information and Modeling · Jun 5, 2026Peer-reviewedBioinformatics

Assessment of the pharmacological and safety profile of the small molecule MP-004 after topical eye drops administration

Araceli Lara-López, María Rodríguez-Hidalgo, Miren Sarasola-Gastesi, Klaudia González-Imaz, Julián Zayas, Maialen Sagartzazu‐Aizpurua, Jose Ignacio Miranda, Ana Espinosa, Adolfo López de Munain, Jesús María Aizpurua, Francisco Javier Gil-Bea, Ainara Vallejo‐Illarramendi, Javier Ruiz‐Ederra

This study evaluates the pharmacological and safety profile of MP-004 after topical eye drops in mice, rabbits, and pigs, showing effective retinal concentrations and minimal systemic exposure.

bioRxiv · Oct 9, 2025 · PreprintPharmacology & Toxicology

Topical administration of novel FKBP12 ligand MP-004 improves retinal function and structure in retinitis pigmentosa models.

Araceli Lara-López, Klaudia González-Imaz, María Rodríguez-Hidalgo, Miren Sarasola-Gastesi, Leire Escudero-Arrarás, Santiago Milla Navarro, Pedro de la Villa, Maialen Sagartzazu‐Aizpurua, Jose Ignacio Miranda, Jesús María Aizpurua, Adolfo López de Munaín, Ainara Vallejo‐Illarramendi, Javier Ruiz‐Ederra

This study evaluates MP-004, a novel FKBP12 ligand, showing improved retinal function and structure in retinitis pigmentosa models through protection against oxidative stress and cell death.

Investigative Ophthalmology & Visual Science · Mar 26, 2025Peer-reviewedNeuroscience

Novel FKBP12 ligand promotes functional improvement in SOD1-G93A ALS mice

Laura Moreno‐Martínez, Núria Gaja‐Capdevila, Laura Mosqueira‐Martín, Mireia Herrando‐Grabulosa, Klaudia González-Imaz, Ana Cristina Calvo, Maialen Sagartzazu‐Aizpurua, Leticia Moreno‐García, José Manuel Fuentes, Abraham Acevedo‐Arozena, Jesús María Aizpurua, Jose Ignacio Miranda, Adolfo López de Munaín, Ainara Vallejo‐Illarramendi, Xavier Navarro, , Francisco Javier Gil-Bea

This study tests a novel FKBP12 ligand, MP-010, in ALS mice, showing improved motor function, preserved motor neurons, and extended lifespan.

bioRxiv · Jan 17, 2024 · PreprintNeuroscience